All In Biotech

Drug Trial Radar · NCT07162116

A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

A Single-center, Randomized, Double-blind, Placebo- and Positive Drug (Open-label Design) Controlled Phase I Clinical Study to Evaluate the Effect of a Single Oral Dose of XY0206 Tablets on QTc Interval in Healthy Chinese Participants.

Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Jul 6, 2025

Primary completion

Dec 1, 2025

Study completion May 2026

Sponsor

Sponsor type
Industry
First posted
Sep 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study plans to enroll 45 (Groups A, B, and C) to 75 healthy participants (including the sample size of other potential dose groups). The participants will be divided into three dose groups: 37.5 mg, 75 mg, and 150 mg. After taking the corresponding investigational product, participants are required to complete test procedures including QTc interval measurement , blood sampling, and vital sign monitoring. The entire test process lasts for 3 days. On the third day, after participants complete laboratory tests and are assessed by physicians as meeting the discharge criteria, they can be discharged.

Conditions

  • Acute Myeloid Leukemia With FLT3/ITD Mutation

Interventions

  • XY0206Drug

    12.5 mg/table,On the morning of the day of dosing , subjects received XY0206 tablets orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg);Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg);Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)

  • Moxifloxacin (400 mg)Drug

    400mg,On the morning of the day of dosing , subjects received moxifloxacin orally on an empty stomach

  • XY0206 PlaceboOther

    12.5mg/table,On the morning of the day of dosing, subjects received XY0206 placebo orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg);Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg);Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. QT/QTcTime frame: 48 hours after drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PKUCare Luzhong Hospital

    Zibo, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.